Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-123 Lotion vs Tazorac Cream in Acne Vulgaris
NCT02938494Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Jul 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tazarotene in acne vulgaris (4 arms), sponsored by Valeant Pharmaceuticals. Primary endpoints: Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12, Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12 and 1 more. Started Nov 2015; status: completed.
02
Drugs
tazarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02938494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938494.